Chiara Chiruzzi

Is HER2-Low a New Clinical Entity or Merely a Biomarker for an Antibody Drug Conjugate?

Heidi Chwan Ko, Rebecca A. Previs, Kyle C. Strickland, Jon Klein et autres

Key Summary PointsSince the U.S. Food and Drug Administration (FDA) approval of trastuzumab deruxtecan (T-DXd) for advanced HER2-low breast cancer, researchers and clinicians have raised an important question of whether HER2-low should be considered as a separate clinical entity with distinct molecular …

us, gb (code pays fourni par la source)

Phase 1b dose-finding study of avelumab (anti-PD-L1) + axitinib in treatment-naïve patients with advanced renal cell carcinoma

James Larkin, Brian I. Rini, Paul Nathan, Fiona C. Thistlethwaite et autres

gb, us, it (code pays fourni par la source)

Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.

James Larkin, Michael S. Gordon, Fiona C. Thistlethwaite, Paul Nathan et autres

TPS4580 Background: Targeted agents have improved outcomes in advanced renal cell carcinoma (aRCC), but patients (pts) inevitably develop resistance. Programmed death-1 receptor ligand (PD-L1) is a key therapeutic target in the reactivation of the immune response against multiple cancers, including RCC. Avelumab* …

gb, us (code pays fourni par la source)

PO-0856: Clinical and dosimetric issues of VMAT craniospinal irradiation for paediatric medulloblastoma

Stefano Meroni, Tommaso Giandini, Barbara Diletto, Emilia Pecori et autres

≤1mm.The shorter treatment delivery was superior for three patterns, while the longer treatment was preferred in the case of temporal displacement of the prostate. Conclusion:The treatment time for extreme hypofractionation of prostate cancer is reduced to less than half the time per …

it (code pays fourni par la source)

Overall Treatment Time and Charlson Score Impact on Toxicity of Intensity Modulated Arc Therapy With Simultaneous Integrated Boost to Prostate for Intermediate- or High-Risk Prostate Cancer

Ferran Ferrer, Guillermo Méndez, Chiara Chiruzzi, Hernán Letelier et autres

es, mx, it (code pays fourni par la source)

EP-1229: Overall treatment time and toxicity of IMAT with integrated boost for intermediate or high-risk prostate cancer

Ferran Ferrer, Hernán Letelier, Ana Maria Boladeras, Rosa Ruiz Piñeiro et autres

Conclusions: Sng and Sep plans were very similar from the dosimetric (D98, D95, D50, D02) and volumetric (V40) point of view.However, in terms of dose delivery (Time, MU), differences were remarkable.This may ecologically profitable and save patient times.These differences were unfluctuating, even …

es (code pays fourni par la source)

HIGH GRADE GLIOMAS AND DIPG

Carl Friedrich Classen, Doreen William, Michael Linnebacher, A. Farhod et autres

RADIATION ONCOLOGY

Beena Kunheri, Asha Arjunan, Preethi Krishnan, Beena Pillai et autres

PO-0698: Clinical predictors of acute skin erythema in patients undergoing breast irradiation

Marco De Santis, Laura Lozza, T. Rancati, M. Carrara et autres

PO-0700: Development of a predictive spectrophotometry-based model for skin erythema in patients treated for breast cancer

Tommaso Giandini, C. Pariani, M. Carrara, Laura Lozza et autres

EP-1252: Preliminary outcomes and toxicity in anal cancer treated with definitive VMAT chemoradiotherapy

Elisa Ciurlia, Francesca Valvo, Anna Cavallo, B. Avuzzi et autres

Is the Standardized Uptake Value of FDG-PET/CT Predictive of Pathological Complete Response in Locally Advanced Rectal Cancer Treated with Capecitabine-Based Neoadjuvant Chemoradiation?

Chiara Bampo, Alessandra Alessi, Simona Fantini, Gaia Bertarelli et autres

OBJECTIVES: Our aim was to assess FDG-PET/CT as a surrogate biomarker of the pathological complete response in locally advanced rectal cancer treated with neoadjuvant chemoradiation. METHODS: T3-4 and/or N+ rectal cancer patients were treated prospectively with capecitabine-based chemoradiation and total mesorectal excision …

it (code pays fourni par la source)